Literature DB >> 18951439

Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study.

Gottfried Kranz1, Dietrich Haubenberger, Bernhard Voller, Martin Posch, Peter Schnider, Eduard Auff, Thomas Sycha.   

Abstract

Mouse units used to quantify the activity of botulinum A toxin preparations are not equivalent and issues concerning efficacy and safety remain with regard to their respective potencies and diffusion qualities in human tissue. We compared the effects of Botox (BOT) and Dysport (DYS) in different doses and dilutions in a human skin model. Eighteen (8 women, 10 men) healthy volunteers, aged 28.4 years +/- 5.7 years were injected intradermally with pure saline, BOT and DYS at 16 points in the abdomen in random order and in a double-blind condition, using two conversion ratios (1:3 and 1:4) and three different dilution schemes. For an objective outcome, the Ninhydrin sweat test was used to compare the anhidrotic areas. Both preparations showed a linear dose and dilution relationship with similar variances of responses for anhidrosis and hypohidrosis, indicating the same reliability of response. The dose equivalence conversion ratios (BOT: DYS) were 1:1.3 for anhidrosis and 1:1.6 for hypohidrosis (1:1.1-1.5 and 1:1.4-1.8 95% confidence intervals). The diffusion characteristics of both products were similar. A dose equivalence factor of more than 1:2 (BOT:DYS) is not supported by these objective and reproducible data.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18951439     DOI: 10.1002/mds.22336

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  13 in total

Review 1.  Temporal characteristics of botulinum neurotoxin therapy.

Authors:  Frank J Lebeda; Regina Z Cer; Robert M Stephens; Uma Mudunuri
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

2.  Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay.

Authors:  Dirk Dressler; Lizhen Pan; Hans Bigalke
Journal:  J Neural Transm (Vienna)       Date:  2018-06-26       Impact factor: 3.575

3.  Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport.

Authors:  Katja Kollewe; Bahram Mohammadi; Reinhard Dengler; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2010-05-01       Impact factor: 3.575

Review 4.  Comparison and overview of currently available neurotoxins.

Authors:  Thomas J Walker; Steven H Dayan
Journal:  J Clin Aesthet Dermatol       Date:  2014-02

5.  Botulinum toxin type A for the management of glabellar rhytids.

Authors:  Anne Marie Tremaine; Jerry L McCullough
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-04-07

Review 6.  Best clinical practice in botulinum toxin treatment for children with cerebral palsy.

Authors:  Walter Strobl; Tim Theologis; Reinald Brunner; Serdar Kocer; Elke Viehweger; Ignacio Pascual-Pascual; Richard Placzek
Journal:  Toxins (Basel)       Date:  2015-05-11       Impact factor: 4.546

7.  Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis.

Authors:  Hanan Mohamed El Kahky; Heba Mahmoud Diab; Dalia Gamal Aly; Nehal Magdi Farag
Journal:  Dermatol Res Pract       Date:  2013-10-22

Review 8.  Botulinum toxin type A products are not interchangeable: a review of the evidence.

Authors:  Mitchell F Brin; Charmaine James; John Maltman
Journal:  Biologics       Date:  2014-10-06

Review 9.  Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?

Authors:  Avram Fraint; Padmaja Vittal; Cynthia Comella
Journal:  Ther Clin Risk Manag       Date:  2016-02-05       Impact factor: 2.423

10.  A Randomized, Comparative Study to Evaluate Efficacy and Safety of Two Injection Volumes of AbobotulinumtoxinA in Treatment of Glabellar Lines.

Authors:  Anna Rostedt Punga; Mohammad Alimohammadi; Dan Fagrell; Frida Nyberg; Diane Rees; Cindy Wong
Journal:  Dermatol Surg       Date:  2016-08       Impact factor: 3.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.